SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:prod.swepub.kib.ki.se:148397283"
 

Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:148397283" > Results of a multic...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003312naa a2200529 4500
001oai:prod.swepub.kib.ki.se:148397283
003SwePub
008240701s2022 | |||||||||||000 ||eng|
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1483972832 URI
024a https://doi.org/10.1038/s41409-021-01551-z2 DOI
040 a (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Bethge, WA4 aut
2451 0a Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients
264 c 2021-12-24
264 1b Springer Science and Business Media LLC,c 2022
520 a Hematopoietic stem cell transplantation (HSCT) from haploidentical donors is a viable option for patients lacking HLA-matched donors. Here we report the results of a prospective multicenter phase I/II trial of transplantation of TCRαβ and CD19-depleted peripheral blood stem cells from haploidentical family donors after a reduced-intensity conditioning with fludarabine, thiotepa, and melphalan. Thirty pediatric and 30 adult patients with acute leukemia (n = 43), myelodysplastic or myeloproliferative syndrome (n = 6), multiple myeloma (n = 1), solid tumors (n = 6), and non-malignant disorders (n = 4) were enrolled. TCR αβ/CD19-depleted grafts prepared decentrally at six manufacturing sites contained a median of 12.1 × 106 CD34+ cells/kg and 14.2 × 103 TCRαβ+ T-cells/kg. None of the patients developed grade lll/IV acute graft-versus-host disease (GVHD) and only six patients (10%) had grade II acute GVHD. With a median follow-up of 733 days 36/60 patients are alive. The cumulative incidence of non-relapse mortality at day 100, 1 and 2 years after HSCT was 5%, 15%, and 17% for all patients, respectively. Estimated probabilities of overall and disease-free survival at 2 years were 63% and 50%, respectively. Based on these promising results in a high-risk patient cohort, haploidentical HSCT using TCRαβ/CD19-depleted grafts represents a viable treatment option.
700a Eyrich, M4 aut
700a Mielke, Su Karolinska Institutet4 aut
700a Meisel, R4 aut
700a Niederwieser, D4 aut
700a Schlegel, PG4 aut
700a Schulz, A4 aut
700a Greil, J4 aut
700a Bunjes, D4 aut
700a Brecht, A4 aut
700a Kuball, J4 aut
700a Schumm, M4 aut
700a Vucinic, V4 aut
700a Wiesneth, M4 aut
700a Bonig, H4 aut
700a Westinga, K4 aut
700a Biedermann, S4 aut
700a Holtkamp, S4 aut
700a Karitzky, S4 aut
700a Malchow, M4 aut
700a Siewert, C4 aut
700a Handgretinger, R4 aut
700a Lang, P4 aut
710a Karolinska Institutet4 org
773t Bone marrow transplantationd : Springer Science and Business Media LLCg 57:3, s. 423-430q 57:3<423-430x 1476-5365x 0268-3369
856u https://www.nature.com/articles/s41409-021-01551-z.pdf
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:148397283
8564 8u https://doi.org/10.1038/s41409-021-01551-z

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy